PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?

preview_player
Показать описание
Recording of the live webinar, broadcast on June 26, 2018

In this webinar, William Hope talked about the role of pharmacokinetics and pharmacodynamics for antimicrobial drug development. He discussed the EMA guideline on the use of PK/PD and basic studies to inform dose finding strategies and also advised on realistic benchmarking, endpoints, and interpretation of study results.

Moderator: Ursula Theuretzbacher
Speaker: William Hope

* This presentation was also part of the GARDP and CARB-X co-organized session ‘Expediting antibacterial development: core lessons and key tools for a rocky road’ at the 28th ECCMID in Madrid in April 2018. *

  1. GARDP
  2. antimicrobial
  3. REVIVE
  4. GARDP
  5. Global Antibiotic Research & Development Partnership
  6. DNDi
Рекомендации по теме
PK-PD in support 1:29:44

PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?

Drug Development Process 0:32:24

Drug Development Process - TOX, ADME, PK/PD, Clinical POC and Drug Approval

Pk/pd of antibiotics 0:24:06

Pk/pd of antibiotics

Accelerating Precision Medicine: 0:34:16

Accelerating Precision Medicine: Leveraging PK/PD Modelling for Optimized Therapeutic Strategies

PK/PD murine infection 1:26:05

PK/PD murine infection models: Focus on study elements, variability, and interpretation of results

Optimizing Drug Development 0:42:17

Optimizing Drug Development with Model-Informed Decision Making

Exploratory and Non-Compartmental 1:06:50

Exploratory and Non-Compartmental Analyses of PK PD Data

How to Define 0:55:19

How to Define & Measure Clinical Endpoints to Optimize Your Oncology Drug Dosing

Essentials of Antibiotic 0:36:37

Essentials of Antibiotic Dosing: Pharmacokinetics and Pharmacodynamics

Pre Clinical Track: 0:28:57

Pre Clinical Track: Ophthalmic clinical pharmacokinetic/pharmacodynamic prediction using PBPK model

Accelerating Early Stage 0:59:36

Accelerating Early Stage Develpment with Simulation and Biomarkers

PK/PD Based Stewardship 0:31:54

PK/PD Based Stewardship Decisions: Genotype vs. Phenotype | James S. Lewis II, Pharm. D., FIDSA

Using Clinical Pharmacology 0:55:32

Using Clinical Pharmacology & Pharmacometrics to Accelerate CAR-T Development

Modeling and Simulation 0:11:17

Modeling and Simulation to Support Pediatric Drug Development

Deep Learning for 0:14:17

Deep Learning for PK/PD and Disease Progression Time-Course Predictions using Neural-ODE

Physiologically based pharmacokinetic 0:30:46

Physiologically based pharmacokinetic modeling for the simulation of relevant clinical scenarios

Ep 83 Pharmacokinetics 0:37:50

Ep 83 Pharmacokinetics & Pharmacodynamics Simplified by Ramesh Jayaraman

The development of 0:05:08

The development of optimal dosage of anti-infective agents based on PK/PD.

PK PD Antibiotic 0:34:38

PK PD Antibiotic

A Best Practice 0:55:39

A Best Practice Framework for Applying PBPK Modeling to Pediatric Drug Development

Learn how to 0:40:25

Learn how to streamline PK/PD workflows with Certara’s Integral Data Repository

GastroPlus, PBBM/PKPD to 0:59:31

GastroPlus, PBBM/PKPD to Define Dissolution Safe Space in Support of Registration Specifications

Pharmacodynamic Biomarkers for 3:42:11

Pharmacodynamic Biomarkers for Biosimilar Development and Approval: Day 2

Utilizing a PK/PD 0:15:43

Utilizing a PK/PD model to enable design principles within the gantenerumab Phase 3 Graduate program